

Canadian HIV/AIDS Pharmacists Network
Meeting Minutes
Toronto, Ontario April 25, 2007

Recorded by: Natalie Dayneka- Secretary
Reviewed by: Michelle Foisy- Chair

Members Present:

BC: Linda Akagi, Gloria Tsang
Alberta: Christine Hughes, Michelle Foisy, Jeff Kapler
Sask: Linda Sulz
Ontario: Deborah Yoong, Norman Dewhurst, Pierre Giguere, Natalie Dayneka,
Nimish Patel, Laura Park-Wyllie
Quebec: Maire Courchesne, Niamh Higgins, Line Labbe
NFLD: Debbie Kelly

Regrets: Jinell Mah-Ming, Kathy Lee, Cara Hills, Lizanne Beique, Alice Tseng,
Linda Robinson, Nancy Sheehan, Rachel Therrien

1. Presentations

Laurie Edmiston, the Executive Director of Canadian AIDS Treatment Information Exchange (CATIE), introduced the publications and websites providing information addressing HIV issues.

Action: Michelle to F/U with CATIE for specifics on collaboration.

Laurie Edmiston may be contacted at: 555 Richmond Street West, Suite 505, Box 1104,
Toronto, Ontario M5V 3B1
Phone: 1-800-263-1638 (416-203-7122 ext. 248)
Fax: 416-203-8284
Email: ledmiston@catie.ca Website: [Http://www.catie.ca](http://www.catie.ca)

- b. Dr. Michelle Hladunewich, MD,MSc,FRCP(C)C, Sunnybrook Health Centre, Toronto, Ontario provided a Workshop on HIV and the Kidney focusing on proximal tubular disease, Fanconi's syndrome.

Action: Michelle Foisy to circulate chart of serum electrolytes and oral supplementation based on electrolyte levels.

Action: Michelle will ensure that the presentation by Dr. Hladunewich will be available for posting on the CHAP website.

2. Conference Updates

- a. Niamh Higgins presented a summary of the CROI 2007. Niamh concentrated on pharmacokinetics, drug interactions, pharmacodynamics including pregnancy and pediatrics.
- b. Pierre Giguere presented also presented a summary of CROI 2007 highlighting what is predicted as being important in the future. This includes issues about coreceptor tropism (maraviroc CCR5), raltegravir unboosted, and elvitegravir (GS-9137) boosted.
- c. Pierre Giguere provided an overview of The 8th International Workshop on Clinical Pharmacology and HIV Therapy, Budapest, Hungary 2007. Pierre focused on pharmacokinetics in special populations (renal or hepatic dysfunction or co-infection with hepatitis C). He also covered drug-drug interactions.
- d. Marie Courchesne continued the overview of 8th International Workshop on Clinical Pharmacology and HIV Therapy, Budapest, Hungary 2007. Marie reviewed pharmacokinetic and pharmacodynamic trials as well as drug-drug interactions.

Action: Niamh, Pierre and Marie to forward presentations to Alice for posting on CHAP website.

3. Clinical Forum

- a. Jeff Kapler presented a case of HIV co-morbidity with Hemophilia. The dilemma of picking a drug regimen including a protease inhibitor with a history of bleeding on previous Kaletra. The drug regimen which may be tested includes boosted vs unboosted atazanavir.
- b. Linda Akagi presented the HIV Drug Classes poster and Medication Schedule handout that she collaborated on. As a few versions exist from various drug companies and institutions, the suggestion was made that CHAP could collaborate on a poster with the various HIV medications and accompanying prophylactic medications. It was also suggested that CATIE may be interested in this project.
- c. Laura Park-Wyllie presented the Medication Adherence Support Toolkit (MAST) tool. Although the funding has been exhausted, Laura is looking forward to adapting this tool for usage. When it is finished, it could be linked to the CHAP website. It may also be a potential collaboration with CATIE.
- d. Deborah Yoong presented St. Mike's 4-fold medication scheduler that Tony, Norman and she developed. She would be willing to share this with CHAP members for review and adaptation to your own site. This might be a potential collaboration with CATIE.

Action: Linda, Laura, and Deborah to circulate adherence projects to CHAP members and to Alice for posting on the CHAP website. The Chair can also forward these projects to CATIE for their potential use.

4. Group Membership

a.

- New Members: Gloria Tsang (Oak Tree) will be replacing Dominic Khoo and Susan Rudolph. Norman Dewhurst will replace Laura Park-Wyllie. Line Labbe has requested to become a member of the working group (requested just after the meeting).
- Change of membership status from working group to general membership: Laura Park-Wyllie.
- No longer members: Susan Rudolph

b. The definition of working group membership was reviewed from the 2006/2007 minutes.

Working Group Membership Criteria:

- geographical/ provincial representation
- active in at least one project every two years (not necessarily a research project)
- primary practice or active interest in HIV
- attend a minimum of one CHAP meeting every two years
- in general, there is space for 20 working group members

General Membership Criteria:

- any pharmacy in Canada can be a general member of CHAP
- pharmacists can be added to the list-serve for the e-mail discussions
- any pharmacist can attend the annual CHAP meeting, however travel grants are only available for the Working Group members

Allocation of Working Group Positions for 2006/07:

- Some of the positions might be shared (share travel grant) with other members who are from a similar geographic area. It was decided that Calgary, Montreal, and Edmonton would each have 2 travel grants that could be divided as they see fit.

c. Working Group Members for 2007/2008 are:

B.C.: Linda Akagi, Gloria Tsang

Alberta: Edmonton: Christine Hughes, Michelle Foisy, Cara Hills (share 2 spots)

Calgary: Kathy Lee, Jinell Mah-Ming, Jeff Kapler (share 2 spots)

Sask: Linda Sulz

Ontario: Toronto: Deborah Yoong, Alice Tseng, Norman Dewhurst

Ottawa: Lizanne Beique, Pierre Giguere, Natalie Dayneka, Charles Laporte
Windsor: Linda Robinson
Quebec: Quebec City
Montreal: Marie Courchesne, Nancy Sheehan, Rachel Therrien, Line Labbe (share 2 spots)
NFLD: Debbie Kelly

5. Allocation of Travel Grants 2007/2008:
 - There are a total of 20 travel grants available annually to assist members in attending the meeting. The grant has ranged from \$750 to \$1250 per member.
 - It was decided that there would be 19 designated grants with 1 floating grant for the Chairperson.
6. Travel Grant Policy
 1. The allocation of travel grants was re-visited. If a non-working group member representing a working group member attends, the non-working group member is eligible for the travel grant. A maximum of 2 representatives will receive travel grants per working site.
 2. A working group member from out of town will receive \$1,000 travel grant while a working group member from the host town will receive \$500. (Recorded vote: 4 in favour of \$1,000 per every member, 8 in favour of \$1,000 outside town and \$500 from the host town.).
 3. If there is extra space (meeting is not running at full capacity) or funding in a given year, requests for additional travel grants will be handled on a first-come, first-serve basis. For instance, if all pharmacists from Calgary wish to attend in a given year and there is extra space, then all three pharmacists would obtain the travel grant. This applies to Edmonton and Montreal as well.

Chairperson Grant:

- As compensation for chairing the group, the Chair will receive an additional \$2000 travel grant to attend a conference of choice.

7. 2007/2008 CHAP Positions and functions:

Chair: Natalie Dayneka

- coordinate CHAP 2008 meeting (Montreal- location TBA)
- procure funding, speakers for meeting
- review group membership roster (working group and general membership)

Action: Natalie to obtain updated roster from Alice and circulate to CHAP for updates/edits.

Secretary: Linda Akagi

- assist Chair with above tasks
- record minutes at CHAP meeting
- coordinate newsletter

Roster Update: Alice Tseng

Treasurer: Alice Tseng, Deborah Yoong

Action: Michelle to ask Alice if she wants to continue to update the roster and function as treasurer. (Yes Alice is looking after this).

8. Terms of Reference

It was decided that the group requires Terms of Reference.

Action: Jeff Kapler has agreed to prepare a draft of the Terms of Reference. These will be circulated and voted on by email so that everyone in the working group can vote.

9. Newsletter sections:

It was decided that the Newsletter should be continued as it demonstrates that the group is active and receiving recognition for our work in the field of HIV. The section on upcoming conferences and literature research will no longer be included. The sections of the newsletter will be: 1) new members, 2) membership recognition, 3) research update and 4) E-mail correspondence.

The following sections will be the responsibility of:

Newsletter Editor: Secretary

Research Update: Secretary

New Members and Membership Recognition: Secretary

E-mail Correspondence: Marie Courchesne

Action: Chair to determine location of next CAHR meeting and book meeting room and secure funding as soon as possible. Chair to contact new potential members and review working group roster. Secretary to coordinate 3 newsletters annually- fall, winter and spring.

10. Research Updates:

- Nelfinavir TDM study (Line Labbe)
 - 5 sites are participating- B.C., Sask, Ottawa, Montreal Chest and Halifax
 - Continuing to recruit patients
- Steroid and Protease Inhibitor Interaction Study (Lizanne Beique)
 - **Action: Lizanne has postponed this study due to her maternity leave**

- c) Nucleoside backbone study (Abacavir/ddI and abacavir/tenofovir) (Christine Hughes)
 - the protocol has been submitted to ethics and data collection will occur over the summer.
 - **Action: Christine presenting at this CHAR 2007**
- d) Tenofovir/ddI backbone study (Christine Hughes)
 - the data had been analyzed in the Edmonton site.
 - **Action: Christine is presenting at this CHAR 2007**

11. 2007/08 New CHAP Initiatives:

- a) Abacavir Hypersensitivity review paper (Michelle Foisy)
 - **Action: Michelle will ask volunteers from the group to review sections of this paper.**
 - Goal is to develop a clinical tool for diagnosis of ABC HSR
 - An Abacavir Hypersensitivity Reaction Algorithm from Michelle Foisy was circulated as part of the review article.

- b) Abacavir Hypersensitivity (HLA- B5701) testing. Pierre asked the group if there was support for a collaborate effort of pooling testing results to publish the group experience.

Action: Pierre to send an email to see if participants and their centres would be interested in sharing abacavir HLA B5701 hypersensitivity testing results.

12. Sponsorship

1. The funding for Dr. Hladunewich was provided as an unrestricted grant directly to CHAP.
2. Sponsorship of the 2007 meeting was provided by Gilead Sciences as an unrestricted educational grant of \$25,000.
3. Pfizer sponsored Dr. Rodger MacArthur's resistance workshop held on April 26th.

April 25, 2007 adjournment 1730h.